Mohammad Ahmad

706 total citations
19 papers, 348 citations indexed

About

Mohammad Ahmad is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Mohammad Ahmad has authored 19 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Genetics. Recurrent topics in Mohammad Ahmad's work include Cancer-related Molecular Pathways (5 papers), Glioma Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mohammad Ahmad is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Glioma Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mohammad Ahmad collaborates with scholars based in United States, Egypt and Canada. Mohammad Ahmad's co-authors include Rod Bremner, Christophe Denoyelle, Matthieu Meryet‐Figuière, Laurent Poulain, Louis‐Bastien Weiswald, Jeffrey L. Wrana, Izhar Livne‐Bar, Marek Pacal, Danian Chen and Christian Isaac and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Molecular and Cellular Biology.

In The Last Decade

Mohammad Ahmad

18 papers receiving 347 citations

Peers

Mohammad Ahmad
Yane Gao China
Anja Bukovac Croatia
Caroline Miller United States
Kin‐Fai Cheung Hong Kong
Yudong Zhang China
Samantha Gokhale United States
Aihui Ma China
G. Spatti Italy
Sophie Lehn Sweden
Kwang Seok Lee Germany
Yane Gao China
Mohammad Ahmad
Citations per year, relative to Mohammad Ahmad Mohammad Ahmad (= 1×) peers Yane Gao

Countries citing papers authored by Mohammad Ahmad

Since Specialization
Citations

This map shows the geographic impact of Mohammad Ahmad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Ahmad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Ahmad more than expected).

Fields of papers citing papers by Mohammad Ahmad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Ahmad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Ahmad. The network helps show where Mohammad Ahmad may publish in the future.

Co-authorship network of co-authors of Mohammad Ahmad

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Ahmad. A scholar is included among the top collaborators of Mohammad Ahmad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Ahmad. Mohammad Ahmad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ahmad, Mohammad, et al.. (2024). The possible correlation between miR-762, Hippo signaling pathway, TWIST1, and SMAD3 in lung cancer and chronic inflammatory diseases. Scientific Reports. 14(1). 8246–8246. 1 indexed citations
2.
Ahmad, Mohammad, Louis‐Bastien Weiswald, Laurent Poulain, Christophe Denoyelle, & Matthieu Meryet‐Figuière. (2023). Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk. Journal of Experimental & Clinical Cancer Research. 42(1). 173–173. 66 indexed citations
3.
Somaiah, Neeta, Brian Andrew Van Tine, Bartosz Chmielowski, et al.. (2023). A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).. Journal of Clinical Oncology. 41(16_suppl). e14627–e14627. 3 indexed citations
4.
Shaheen, Montaser, Jennifer Segar, Bartosz Chmielowski, et al.. (2023). A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.. Journal of Clinical Oncology. 41(16_suppl). 9559–9559. 10 indexed citations
5.
Ahmad, Mohammad, Pierre‐Marie Morice, Bernard Lambert, et al.. (2021). The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels. Molecular Oncology. 15(12). 3659–3678. 32 indexed citations
6.
Swiecicki, Paul, Alexander T. Pearson, Jameel Muzaffar, et al.. (2021). Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.. Journal of Clinical Oncology. 39(15_suppl). TPS6094–TPS6094. 2 indexed citations
7.
8.
Ailawadhi, Sikander, Asher Chanan‐Khan, Zi Chen, et al.. (2021). First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).. Journal of Clinical Oncology. 39(15_suppl). 7502–7502. 16 indexed citations
9.
10.
Pearson, Joel D., Katherine Huang, Izhar Livne‐Bar, et al.. (2020). Functional genomics identifies new synergistic therapies for retinoblastoma. Oncogene. 39(31). 5338–5357. 28 indexed citations
11.
Yassin, Ahmed, et al.. (2020). Prevalence of Cardiovascular Diseases and Vascular Risk Factors in Patients with History of Epilepsy/Seizures (4854). Neurology. 94(15_supplement). 1 indexed citations
12.
Tolcher, Anthony W., Hengbang Wang, Jiao Ji, et al.. (2020). Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3512–3512. 1 indexed citations
13.
Ahmad, Mohammad, Bernard Lambert, Florence Joly, et al.. (2019). The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer. Gynecologic Oncology. 156(3). 726–733. 11 indexed citations
14.
Ahmed, Ahmed, et al.. (2018). B Cell Lymphoma-2 (Bcl-2) in Serum Increased with Breast Cancer in Egyptian Women. SHILAP Revista de lepidopterología. 4(3). 296–305. 2 indexed citations
15.
Pacal, Marek, et al.. (2016). A CDK2 activity signature predicts outcome in CDK2-low cancers. Oncogene. 36(18). 2491–2502. 32 indexed citations
16.
Ahmad, Mohammad, et al.. (2014). GRP78 up-regulation leads to hypersensitization to cisplatin in A549 lung cancer cells.. PubMed. 34(7). 3493–500. 13 indexed citations
17.
Ahmad, Mohammad, et al.. (2014). Protective and therapeutic effects of cannabis plant extract on liver cancer induced by dimethylnitrosamine in mice. SHILAP Revista de lepidopterología. 50(3). 241–251. 18 indexed citations
18.
19.
Talluri, Srikanth, Christian Isaac, Mohammad Ahmad, et al.. (2009). A G1 Checkpoint Mediated by the Retinoblastoma Protein That Is Dispensable in Terminal Differentiation but Essential for Senescence. Molecular and Cellular Biology. 30(4). 948–960. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yane Gao Breakdown of academic impact, for papers by Anja Bukovac Breakdown of academic impact, for papers by Caroline Miller Breakdown of academic impact, for papers by Kin‐Fai Cheung Breakdown of academic impact, for papers by Yudong Zhang Breakdown of academic impact, for papers by Samantha Gokhale Breakdown of academic impact, for papers by Aihui Ma Breakdown of academic impact, for papers by G. Spatti Breakdown of academic impact, for papers by Sophie Lehn Breakdown of academic impact, for papers by Kwang Seok Lee
Rankless by CCL
2026